scholarly journals Synchronous Quadruple Lung Cancer Treated Curatively by Photodynamic Therapy

1996 ◽  
Vol 3 (2) ◽  
pp. 115-119
Author(s):  
Makoto Saito ◽  
Harubumi Kato ◽  
Chimori Konaka ◽  
Tetsuya Okunaka ◽  
Kinnya Furukawa ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Squamous Cell Carcinoma ◽  
Photodynamic Therapy ◽  
Early Stage ◽  
Fiberoptic Bronchoscopy ◽  
Histologic Type ◽  
Early Stage Lung Cancer ◽  
Poor Pulmonary Function ◽  
Stage Lung Cancer

A 54-year-old male was diagnosed as having synchronous quadruple early stage lung cancer. All four tumors showed the same histologic type of in-situ or microinvasive squamous cell carcinoma, but existed independently in different bronchi. Photodynamic therapy of these four lesions was successfully performed by fiberoptic bronchoscopy because of the patient's poor pulmonary function. The patient is alive and well 51 months later.

scholarly journals Photodynamic Therapy of Lung Cancer With Bronchial Artery Infusion of Photofrin

1996 ◽  
Vol 2 (4) ◽  
pp. 203-206 ◽  
Author(s):  
Tetsuya Okunaka ◽  
Harubumi Kato ◽  
Chimori Konaka ◽  
Kinya Furukawa ◽  
Masahiko Harada ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Photodynamic Therapy ◽  
Early Stage ◽  
Bronchial Artery ◽  
Arterial Infusion ◽  
Early Stage Lung Cancer ◽  
Hospitalization Period ◽  
Bronchial Arterial Infusion ◽  
Skin Photosensitivity ◽  
Stage Lung Cancer

Photodynamic therapy (PDT) utilizing Photofrin is proving to be effective for the treatment of early stage lung cancer. However, wider clinical applications of Photofrin as a photosensitizer for various cancers are hampered by potentially serious and prolonged skin photosensitivity. To prevent these side effects and reduce the hospitalization period, we recently gave reduced doses of Photofrin by bronchial arterial infusion. Five patients with endoscopically evaluated minimally invasive carcinoma of the lung were given 0.7 mg/kg of Photofrin by bronchial arterial infusion 48 hr before PDT. Complete remission was obtained in all 5 cases and no case showed skin photosensitivity when exposed to sunlight under careful surveillance at one week after PDT.

New aspects of photodynamic therapy for central type early stage lung cancer

2011 ◽  
Vol 43 (7) ◽  
pp. 749-754 ◽  
Author(s):  
Norihiko Ikeda ◽  
Jitsuo Usuda ◽  
Harubumi Kato ◽  
Taichiro Ishizumi ◽  
Shuji Ichinose ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Photodynamic Therapy ◽  
Early Stage ◽  
Early Stage Lung Cancer ◽  
Central Type ◽  
Stage Lung Cancer

Photodynamic therapy using Laserphyrin for centrally located early stage lung cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 7229-7229 ◽  
Author(s):  
J. Usuda ◽  
H. Kato ◽  
T. Okunaka ◽  
K. Furukawa ◽  
H. Honda ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Photodynamic Therapy ◽  
Early Stage ◽  
Stage I ◽  
University Hospital ◽  
Early Stage Lung Cancer ◽  
Endobronchial Ultrasonography ◽  
Tokyo Medical ◽  
Medical University ◽  
Stage Lung Cancer

7229 Background: In central type early stage lung cancer, the tumor must be located only as far as the segmental bronchi and be carcinoma in situ or with only limited invasion into the bronchial wall. Laserphyrin (mono-L-aspartyl chlorine e6, NPe6) is a second generation photosensitize and approved by the Japanese government and has been on sale from June 2004. Methods: Four h after the administration of Laserphyrin 40 mg/m2, we irradiated using diode laser (100 mJ/cm2). Before PDT, we evaluated the tumor lesions and tumor depth using autofluorescence bronchoscopy and endobronchial ultrasonography (EBUS), and we confirmed the area of laser irradiation. Results: From February 1980 to December 2005, a total number of 204 patients with 264 lesions of centrally located early stage lung cancer underwent photodynamic therapy (PDT) in the Department of Thoracic Surgery, Tokyo Medical University Hospital. There were 185 clinical stage 0 lesions and 79 stage I lesions. CRs and PRs were obtained in 224 lesions (84.8%) and 40 lesions (15.2%) out of 264 lesions. From July 2004 to December 2005, we performed Laserphyrin-PDT for 28 lesions of centrally located early stage lung cancer in Tokyo Medical University Hospital. The rate of CR was 92.9% (26 lesions) in 28 lesions. For Laserphyrin-PDT, Skin photosensitivity was very low and the clean-up bronchoscopies were not frequently needed, and the period of hospitalization was shorter compared to that for Photofrin-PDT. Conclusions: We conclude that PDT using Laserphyrin will be a standard option for stage 0 (TisN0M0) and stage I (T1N0M0) centrally located early stage lung cancer. No significant financial relationships to disclose.

scholarly journals Effects of Photodynamic Therapy in Inoperable Early Stage Lung Cancer Patients.

Haigan ◽  
1995 ◽  
Vol 35 (2) ◽  
pp. 127-132
Author(s):  
Naofumi Takehara ◽  
Yoshinobu Ohsaki ◽  
Satoru Fujiuchi ◽  
Shuji Yamaguchi ◽  
Yuji Akiba ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Photodynamic Therapy ◽  
Cancer Patients ◽  
Early Stage ◽  
Early Stage Lung Cancer ◽  
Lung Cancer Patients ◽  
Stage Lung Cancer
Sign in / Sign up

Export Citation Format

Share Document